依帕司他联合普罗布考治疗早期糖尿病肾病的临床观察  

Epalrestat combined probucol treatment of early diabetic nephropathy.

作　　者：谭静宇[1] 张勇[1] 陈卓[1] 

机构地区：[1]四川绵竹市人民医院内一科,四川绵竹618200

出　　处：《河南中医》2014年第B11期157-158,共2页Henan Traditional Chinese Medicine

摘　　要：目的探讨依帕司他联合普罗布考治疗早期糖尿病肾病的临床疗效.方法：将64 例糖尿病肾病患者随机分为两组,每组各32 例,常规控制血糖在理想范围,治疗组同时加用依帕司他、普罗布考联合治疗,对治疗3 个月后两组患者的疗效、UAE、Scr、BUN、TC、TG、LDL-C、ox-LDL、CRP 进行比较.结果：治疗3个月后,治疗组总有效率达到90.6%,显著优于对照组;3 个月后对照组患者UAE 明显低于对照组（P〈0.01）,且两组患者肾功能无显著性差异（P〉0.05）,同时监测患者TC、TG、LDL-C、ox-LDL、CRP 较对照组有显著性差异（P〈0.01）.结论：依帕司他联合普罗布考治疗早期糖尿病肾病患者临床疗效确切.ObjectiveTo observe the clinical efficacy of Explore epalrestat combined probucol treatment of early diabetic nephropathy.Methods：The 64 cases of diabeticnephropathy were randomly divided into two groups, each group 32 cases,control of blood glucose in the ideal range,combined treatment group epalrestat probucol treatment,theefficacy of the two groups of patients 3 months after treatment,UAE,Scr,BUN,TC,TG,LDL-C,ox-LDL,CRP were compared.Results：After 3 months of treatment, the treatmentgroup,the total efficiency of 90.6%,significantly better than the control group;three months after the UAE was significantly lower than the control group of patients in the controlgroup（P〈0.01）,while monitoring the patient TC,TG,LDL-C there was a significant difference（P〈0.01）,ox-LDL,CRP compared with the control group.Conclusion：Epalrestat combinedprobucol treatment of early clinical efficacy in patients with diabetic nephropathy.

关 键 词：依帕司他 普罗布考 糖尿病肾病 

分 类 号：R969[医药卫生—药理学]